The antibody-drug conjugate Rovalpituzumab tesirine (Rova-T, AbbVie), composed of a human DLL3-specific mAb, the DNA-crosslinking agent pyrrolobenzodiazepine, and a protease-cleavable linker, effectively eradicated neuroendocrine CSCs in vivo and abolished chemotherapy-resistant SCLC and large cell neuroendocrine carcinoma (LCNEC) xenograft growth [239]. This evidence concerns the gene DLL3 and small cell lung carcinoma.